Results of the phase II trial Low-PV: Ropeginterferon versus phlebotomy for low risk PV

At the 25th European Hematology Association (EHA) Annual Congress, our Steering Committee member Tiziano Barbui...

U.S. FDA grants orphan drug designation for PTG-300 for the treatment of polycythemia vera

PTG-300, an injectable hepcidin mimetic peptide, has received orphan drug designation by the U.S. Food and...

Should ropeginterferon become SoC for all patients with low-risk PV?

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Tiziano Barbui, L'ospedale Papa...

FDA accepts Biologics License Application of ropeginterferon alfa-2b for polycythemia vera

On June 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application (BLA)...

Real-world experience with ruxolitinib in myelofibrosis

Ruxolitinib is a Janus kinase (JAK) 1 and JAK 2 inhibitor approved for primary and secondary intermediate-/high-risk myelofibrosis (MF). The...

Trial update of the MANIFEST study of CPI-0610 in patients with myelofibrosis from EHA 2020

MANIFEST (NCT02158858) is a phase II clinical trial of CPI-0610, a small molecule inhibitor of bromodomain...

Long-term safety analyses of momelotinib in patients with myelofibrosis

Momelotinib is a selective and orally available inhibitor of Janus kinase (JAK) 1, JAK2, and activin A type 1 receptor (ACVR1)...

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

Interview with John Mascarenhas, Icahn School of Medicine at Mount Sinai during the 25th Congress of the European...

Final phase II results of the SMAC mimetic LCL161 for intermediate/high-risk myelofibrosis

The efficacy and safety of the LCL161 was assessed in patients with relapsed or refractory MF of...

TET2 mutations predict thrombotic risk in patients with polycythemia vera

There is limited data on the role of DTA mutations in the prediction of thrombotic risk in patients with MPN. For...

Review of novel agents for myeloproliferative neoplasms

In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal...

Management of thrombocytopenia in patients with myelofibrosis

Myelofibrosis (MF) is a progressive disease that can either appear de novo (primary MF [PMF]) or occur following a prior diagnosis of...